<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224665</url>
  </required_header>
  <id_info>
    <org_study_id>S1011</org_study_id>
    <secondary_id>SWOG-S1011</secondary_id>
    <secondary_id>NCI-2011-02604</secondary_id>
    <nct_id>NCT01224665</nct_id>
  </id_info>
  <brief_title>S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer</brief_title>
  <official_title>A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Lymphadenectomy may remove tumor cells that have spread to nearby lymph nodes in
      patients with invasive bladder cancer. It is not yet known whether extended pelvic
      lymphadenectomy is more effective than standard pelvic lymphadenectomy during surgery.

      PURPOSE: This randomized phase II trial is studying standard pelvic lymphadenectomy to see
      how well it works compared to extended pelvic lymphadenectomy in treating patients undergoing
      surgery for invasive bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare disease-free survival (DFS) of patients with muscle-invasive urothelial
           carcinoma of the bladder undergoing radical cystectomy with extended pelvic lymph node
           dissection (PLND) or standard pelvic lymphadenectomy.

      Secondary

        -  To compare overall survival (OS) of patients randomized to extended PLND versus those
           randomized to standard pelvic lymphadenectomy.

        -  To evaluate operative time; whether or not nerve sparing was performed, intraoperative,
           peri-operative and 90-day morbidity and mortality; length of hospital stay; histology
           (pure urothelial versus mixed); lymph node counts and lymph node density; adjuvant
           chemotherapy received; and local and retroperitoneal soft tissue recurrence in patients
           randomized to extended PLND versus those randomized to standard pelvic lymphadenectomy.

        -  To collect peripheral blood and two paraffin-embedded blocks of the primary tumor for
           translational medicine studies, including circulating tumor cells (CTCs) and markers of
           epithelial and mesenchymal transition, and correlate these findings with pathologic T
           stage and node metastasis as well as DFS and OS.

      OUTLINE: This is a multicenter study. Patients are stratified according to prior neoadjuvant
      therapy (yes vs no), clinical stage (T2 vs T3 vs T4a), and Zubrod performance status (0-1 vs
      2). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients undergo radical cystectomy and standard pelvic lymphadenectomy.

        -  Arm II: Patients undergo radical cystectomy and extended pelvic lymphadenectomy.

      Blood and tumor specimens may be collected periodically for translational studies.

      After completion of study therapy, patients are followed up periodically for 6 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to 6 years from date of Step 2 Registration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 6 years from date of Step 2 Registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Up to 6 years from date of Step 2 Registration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">620</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>therapeutic conventional surgery therapeutic standard lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>therapeutic conventional surgery therapeutic extended lymphadenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Patients undergo radical cystectomy</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic standard lymphadenectomy</intervention_name>
    <description>Patients undergo standard pelvic lymphadenectomy.</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic extended lymphadenectomy</intervention_name>
    <description>Patients undergo extended pelvic lymphadenectomy</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed urothelial carcinoma of the bladder

               -  Stage T2, T3, or T4a disease

                    -  No clinical stage consistent with a low-risk of node metastasis (CIS only,
                       T1)

                    -  No T4b disease (fixed lesion)

               -  Disease that requires primary radical cystectomy and lymph node dissection for
                  definitive treatment

                    -  No laparoscopic surgery

          -  Predominant urothelial carcinoma with any of the following elements allowed:

               -  Adenocarcinoma

               -  Squamous cell carcinoma

               -  Micropapillary or minor components of other rare phenotype

               -  No pure squamous cell carcinoma or adenocarcinoma

          -  No visceral or nodal metastatic disease proximal to the common iliac bifurcation by
             2-view chest x-ray and abdominal-pelvic imaging by computerized tomography or MRI of
             the abdomen and pelvis

          -  No intra-operative pelvic lymph node involvement (confirmed by frozen section) at or
             above the bifurcation of the common iliac vessels in any of the extended template

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-2

          -  ALT and AST ≤ upper limit of normal (ULN)*

          -  Alkaline phosphatase ≤ ULN*

          -  Not pregnant or nursing

          -  Fertile patients must use an effective contraception

          -  No other prior malignancy except adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, or stage I or II cancer from which the patient is in
             complete remission for the past 5 years

          -  Medically suitable to undergo cystectomy, in the physician's opinion NOTE: *Levels may
             be ≥ ULN provided metastatic disease is excluded using dedicated liver imaging, bone
             scan, or biopsy.

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior partial cystectomy for invasive bladder cancer

          -  No prior pelvic surgery that would obviate a complete extended lymphadenectomy (e.g.,
             aorto-femoral/iliac bypass)

          -  Prior neoadjuvant chemotherapy for this cancer allowed provided it has been completed
             and patient has recovered

          -  No prior pelvic irradiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seth P. Lerner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer I Scott</last_name>
    <phone>210-614-8808</phone>
    <phone_ext>1007</phone_ext>
    <email>jscott@swog.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana B Sparks, M.A.T.</last_name>
    <phone>210-614-8808</phone>
    <phone_ext>1004</phone_ext>
    <email>dsparks@swog.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Los Angeles County-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siamak Daneshmand</last_name>
      <phone>323-865-0451</phone>
      <email>daneshma@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Siamak Daneshmand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siamak Daneshmand</last_name>
      <phone>323-865-0451</phone>
      <email>daneshma@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Siamak Daneshmand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eila C. Skinner</last_name>
      <phone>650-498-7061</phone>
      <email>ccto-office@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Eila C. Skinner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxwell V. Meng</last_name>
      <phone>877-827-3222</phone>
    </contact>
    <investigator>
      <last_name>Maxwell V. Meng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxwell V. Meng</last_name>
      <phone>877-827-3222</phone>
    </contact>
    <investigator>
      <last_name>Maxwell V. Meng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shandra S. Wilson</last_name>
      <phone>720-848-0650</phone>
    </contact>
    <investigator>
      <last_name>Shandra S. Wilson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John W. Colberg</last_name>
      <phone>203-785-5702</phone>
    </contact>
    <investigator>
      <last_name>John W. Colberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A. Poch</last_name>
      <phone>800-456-7121</phone>
      <email>canceranswers@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Michael A. Poch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norm D. Smith</last_name>
      <phone>773-834-7424</phone>
    </contact>
    <investigator>
      <last_name>Norm D. Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus L. Quek</last_name>
      <phone>708-226-4357</phone>
    </contact>
    <investigator>
      <last_name>Marcus L. Quek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trinity J. Bivalacqua</last_name>
      <phone>410-955-8804</phone>
      <email>jhcccro@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Trinity J. Bivalacqua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen A. Boorjian</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Stephen A. Boorjian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert L. Grubb</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Robert L. Grubb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew J. Stephenson</last_name>
      <phone>866-223-8100</phone>
    </contact>
    <investigator>
      <last_name>Andrew J. Stephenson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal S. Pohar</last_name>
      <phone>800-293-5066</phone>
      <email>Jamesline@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Kamal S. Pohar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Portland Veterans Administration Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Parkland Memorial Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur I. Sagalowsky</last_name>
      <phone>214-648-7097</phone>
    </contact>
    <investigator>
      <last_name>Arthur I. Sagalowsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur I. Sagalowsky</last_name>
      <phone>214-648-7097</phone>
    </contact>
    <investigator>
      <last_name>Arthur I. Sagalowsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth P. Lerner</last_name>
      <phone>713-798-1354</phone>
      <email>burton@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Seth P. Lerner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Saint Luke's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth P. Lerner</last_name>
      <phone>713-798-1354</phone>
      <email>burton@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Seth P. Lerner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Audie L Murphy Veterans Affairs Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert S. Svatek</last_name>
      <phone>210-450-3800</phone>
      <email>CTO@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Robert S. Svatek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert S. Svatek</last_name>
      <phone>210-450-3800</phone>
      <email>CTO@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Robert S. Svatek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BCCA-Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter C. Black</last_name>
      <phone>888-939-3333</phone>
    </contact>
    <investigator>
      <last_name>Peter C. Black</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre/Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo A. Rendon</last_name>
      <phone>902-473-6000</phone>
    </contact>
    <investigator>
      <last_name>Ricardo A. Rendon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan I. Izawa</last_name>
      <phone>519-685-8600</phone>
    </contact>
    <investigator>
      <last_name>Jonathan I. Izawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Girish Kulkarni</last_name>
      <phone>416-946-4501</phone>
      <email>clinical.trials@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>Girish Kulkarni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Department of Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>The Research Institute of the McGill University Health Centre (MUHC)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 2R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wassim Kassouf</last_name>
      <phone>514-934-4400</phone>
    </contact>
    <investigator>
      <last_name>Wassim Kassouf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

